Patient-Focused Drug Development: US FDA’s Guidance Development Effort Passes The Mid-Point
Executive Summary
Agency has issued two of four methodological draft guidances required under 21st Century Cures Act and convened workshops on the two documents still to come; industry, patient groups applaud FDA’s initiative but point to gaps in the guidance series, particularly around interactions with the agency on patient experience data and approaches to collecting patient preference information.
You may also be interested in...
Patient-Focused Drug Development, Complex Trial Design May Not Get More Funding In PDUFA VII
US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.
Drug Costs Not A Primary Driver Of Rare Disease Economic Burden
EveryLife Foundation study finds inpatient and outpatient care, not prescription drugs, are the primary excess medical costs associated with rare diseases.
Woodcock Has Big, Quiet Supporter In Her Bid For US FDA Commissioner
Industry groups, along with many rare disease and patient advocacy groups, appear behind the acting commissioner getting the permanent position.